Oppenheimer Holdings Inc. reaffirmed their outperform rating on shares of Amgen, Inc. (NASDAQ:AMGN) in a research report sent to investors on Thursday morning. The brokerage currently has a $189.00 price objective on the medical research company’s stock.
Other analysts also recently issued research reports about the stock. Argus set a $195.00 price target on shares of Amgen and gave the company a buy rating in a report on Saturday, February 11th. Mizuho set a $195.00 price objective on shares of Amgen and gave the company a buy rating in a research report on Friday, March 10th. Vetr lowered shares of Amgen from a strong-buy rating to a buy rating and set a $178.82 price objective for the company. in a research report on Monday, April 3rd. Chardan Capital raised shares of Amgen from a sell rating to a neutral rating in a research report on Tuesday, December 13th. Finally, BMO Capital Markets boosted their price objective on shares of Amgen from $197.00 to $202.00 and gave the company a positive rating in a research report on Friday, February 3rd. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $186.94.
Amgen (NASDAQ:AMGN) traded down 1.01% during midday trading on Thursday, hitting $160.41. 2,906,823 shares of the stock traded hands. The company has a market cap of $118.13 billion, a P/E ratio of 15.67 and a beta of 1.15. The company’s 50 day moving average is $169.01 and its 200-day moving average is $158.67. Amgen has a one year low of $133.64 and a one year high of $184.21.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 2nd. The medical research company reported $2.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.79 by $0.10. Amgen had a net margin of 33.59% and a return on equity of 29.42%. The company had revenue of $5.97 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter in the prior year, the firm earned $2.61 earnings per share. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. On average, equities research analysts forecast that Amgen will post $12.33 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Amgen, Inc. (AMGN) Stock Rating Reaffirmed by Oppenheimer Holdings Inc.” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/04/21/amgens-amgn-outperform-rating-reaffirmed-at-oppenheimer-holdings-inc-updated.html.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Wednesday, May 17th will be issued a dividend of $1.15 per share. The ex-dividend date of this dividend is Monday, May 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.87%. Amgen’s dividend payout ratio (DPR) is 44.92%.
Hedge funds have recently modified their holdings of the company. Concorde Asset Management LLC boosted its stake in shares of Amgen by 5.9% in the first quarter. Concorde Asset Management LLC now owns 2,054 shares of the medical research company’s stock worth $337,000 after buying an additional 114 shares during the period. Hollencrest Securities LLC acquired a new stake in shares of Amgen during the first quarter worth $562,000. V Wealth Management LLC boosted its stake in shares of Amgen by 45.7% in the first quarter. V Wealth Management LLC now owns 13,125 shares of the medical research company’s stock worth $2,148,000 after buying an additional 4,117 shares during the period. Naples Global Advisors LLC boosted its stake in shares of Amgen by 2.2% in the first quarter. Naples Global Advisors LLC now owns 16,942 shares of the medical research company’s stock worth $2,780,000 after buying an additional 365 shares during the period. Finally, James Investment Research Inc. boosted its stake in shares of Amgen by 128.7% in the first quarter. James Investment Research Inc. now owns 10,520 shares of the medical research company’s stock worth $1,726,000 after buying an additional 5,920 shares during the period. 79.04% of the stock is currently owned by institutional investors.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.